悪性固形腫瘍におけるGEN1057の安全性と抗腫瘍活性を評価する試験
悪性固形腫瘍患者におけるGEN1057の安全性と抗腫瘍活性を評価するためのヒト初の非盲検用量漸増試験
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer.
Trial details include:
- The trial duration for an individual participant will be up to approximately 11 months.
- The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months.
Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The trial is a first-in-human (FIH) open-label, multicenter, multinational safety trial.
The dose escalation will evaluate different dose levels by assessing safety, tolerability, and early efficacy signals to determine the expansion dose(s) of GEN1057 as monotherapy, as well as characterizing the pharmacokinetic (PK) profile and immunogenicity in participants with malignant solid tumors who have metastatic or advanced disease.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- SCRI Oncology Partners
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- South Texas Accelerated Research Therapeutics, LLC
-
-
-
-
-
Madrid、スペイン、28050
- Start Madrid Centro Integral Oncologico Clara Campal CIOCC
-
-
Barcelona
-
Barcelona、Barcelona、スペイン、08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
-
Tokyo、日本
- National Cancer Center, Tsukiji 5-1-1
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Advanced and/or metastatic malignant solid tumors, who have progressed on standard of care therapy for whom there is no available standard therapy likely to provide clinical benefit, or who are not candidates for available therapy, and for whom experimental therapy with GEN1057 may be beneficial, in the opinion of the investigator.
- Be at least 18 (or the legal age of consent in the jurisdiction in which the trial is taking place) years of age.
- Have measurable disease according to RECIST v1.1.
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 at screening and on C1D1 pretreatment. Note: If screening ECOG PS is assessed within 3 days prior to C1D1, ECOG PS does not need to be reassessed at C1D1.
- Have a life expectancy of ≥3 months.
Key Exclusion Criteria:
-
Has been exposed to any of the following prior therapies/treatments within the specified timeframes:
- Treatment with an investigational anticancer agent within 28 days or for systemic therapies within 5 half-lives of the drug, whichever is shorter, prior to trial treatment administration.
- Treatment with an investigational drug, including investigational vaccines within 28 days before the planned first dose of trial treatment.
- Prior treatment with live, attenuated vaccines within 28 days prior to initiation of GEN1057. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live, attenuated vaccines and are not allowed. Experimental and/or nonauthorized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations are not allowed.
- Used an invasive investigational medical device within 28 days before the planned first dose of trial treatment.
-
Has clinically significant toxicities from previous anticancer therapies that have not resolved to baseline levels or to grade 1, except for anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy, which must have recovered to ≤ grade 2. There is no limitation for alopecia and hearing impairment from previous therapies.
-
Has known, symptomatic brain metastases. Asymptomatic brain metastases are allowed provided that they have been treated, have been stable for >28 days as documented by radiographic imaging, and do not require prolonged (>14 days) systemic corticosteroid therapy.
-
Has a past or current malignancy other than inclusion diagnosis.
Note: Other protocol-defined inclusion and exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:GEN1057 単独療法
|
Intravenous (IV) infusion IV infusion/orally by mouth. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
治療中に発生した有害事象(AE)のある参加者の数
時間枠:初回投与から安全性追跡期間終了まで(約5ヶ月)
|
初回投与から安全性追跡期間終了まで(約5ヶ月)
|
|
|
Number of Participants With Dose Limiting Toxicities (DLTs)
時間枠:Up to 21 days
|
DLTs will be graded for severity according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v5.0. |
Up to 21 days
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
GEN1057の最大血漿濃度(Cmax)
時間枠:治療終了(約4か月)までの複数の時点での投与前および投与後
|
治療終了(約4か月)までの複数の時点での投与前および投与後
|
|
|
GEN1057 の Cmax (Tmax) に達するまでの時間
時間枠:治療終了(約4か月)までの複数の時点での投与前および投与後
|
治療終了(約4か月)までの複数の時点での投与前および投与後
|
|
|
GEN1057 の時間ゼロから最後の定量可能なサンプル (AUC0-last) までの濃度時間曲線下面積 (AUC)
時間枠:治療終了(約4か月)までの複数の時点での投与前および投与後
|
治療終了(約4か月)までの複数の時点での投与前および投与後
|
|
|
GEN1057の半減期(t1/2)
時間枠:治療終了(約4か月)までの複数の時点での投与前および投与後
|
治療終了(約4か月)までの複数の時点での投与前および投与後
|
|
|
GEN1057 の血漿からのクリアランス (CL)
時間枠:治療終了(約4か月)までの複数の時点での投与前および投与後
|
治療終了(約4か月)までの複数の時点での投与前および投与後
|
|
|
Number of Participants with Anti-drug Antibodies (ADAs) to GEN1057
時間枠:Up to approximately 11 months
|
Serum samples will be screened for ADAs binding to GEN1057 and the titer of confirmed positive samples will be reported. |
Up to approximately 11 months
|
|
Objective Response Rate (ORR)
時間枠:Up to approximately 11 months
|
The ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors (RECIST) version (v) 1.1 as assessed by the investigator. |
Up to approximately 11 months
|
|
Duration of Response (DOR)
時間枠:Up to approximately 11 months
|
DOR is defined as the time from the first documentation of response (CR or PR) to the date of progressive disease (PD) or death, whichever occurs earlier based on RECIST v1.1 as assessed by the investigator. |
Up to approximately 11 months
|
|
Time to Response (TTR)
時間枠:Up to approximately 11 months
|
TTR is defined as the time from Cycle 1 Day 1 (C1D1) to the first documentation of objective response (CR or PR) in participants achieving PR or CR based on RECIST v1.1 as assessed by the investigator. |
Up to approximately 11 months
|
|
Disease Control Rate (DCR)
時間枠:Up to approximately 11 months
|
DCR is defined as the percentage of participants with BOR of CR, PR, or stable disease (SD) based on RECIST v1.1 as assessed by the investigator. |
Up to approximately 11 months
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Study Official、Genmab
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- GCT1057-01
- 2024-513563-75-00 (Ctis)
- jRCT2031240508 (レジストリ識別子:Japan Registry of Clinical Trials)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。